Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

Phase 2

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Natalizumab
Drug: Methylprednisolone

First Posted Date: 2014-06-26

Last Posted Date: 2020-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT02176031

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia

Not Applicable

Terminated

Conditions: Acute Respiratory Distress Syndrome (ARDS)

Interventions: Device: Airway Pressure Release Ventilation (APRV)
Other: Low-tidal volume ventilation
Drug: Methylprednisolone
Other: Restrictive fluid therapy
Drug: sedo-analgesia titration
Other: Protocolized early enteral nutrition
Other: Protocolized supportive care
Other: Biomarker Assay

First Posted Date: 2014-06-19

Last Posted Date: 2017-05-19

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 52

Registration Number: NCT02167698

Locations: 🇮🇳
Pediatric Intensive care unit, Division of Pediatric Critical Care, Advanced Pediatrics Center, Post-graduate Institute of Medical Education & Research, Chandigarh, India

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Phase 3

Active, not recruiting

Conditions: Ann Arbor Stage IIIB Hodgkin Lymphoma
Childhood Hodgkin Lymphoma
Ann Arbor Stage IVB Hodgkin Lymphoma
Classic Hodgkin Lymphoma
Ann Arbor Stage IIB Hodgkin Lymphoma
Ann Arbor Stage IVA Hodgkin Lymphoma

Interventions: Biological: Bleomycin Sulfate
Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Methylprednisolone
Other: Pharmacological Study
Drug: Prednisone
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Vincristine Sulfate

First Posted Date: 2014-06-18

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 600

Registration Number: NCT02166463

Locations: 🇺🇸
Bronson Methodist Hospital, Kalamazoo, Michigan, United States
🇺🇸
Corewell Health Children's, Royal Oak, Michigan, United States
🇺🇸
Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States

and more 196 locations

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

Phase 4

Completed

Conditions: Implant or Graft; Rejection

Interventions: Drug: Belatacept
Drug: Tacrolimus
Drug: Mycophenolate
Drug: rATG
Drug: Methylprednisolone
Procedure: Renal transplant

First Posted Date: 2014-06-02

Last Posted Date: 2021-02-10

Lead Sponsor: Columbia University

Target Recruit Count: 57

Registration Number: NCT02152345

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States

A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis

Phase 4

Completed

Conditions: Wegener's Granulomatosis or Microscopic Polyangiitis

Interventions: Drug: Methylprednisolone
Drug: Prednisone
Drug: Rituximab

First Posted Date: 2014-04-16

Last Posted Date: 2022-07-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT02115997

Locations: 🇮🇳
Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India
🇮🇳
St. John's Medical College Hospital; Rheumatology, Bangalore, India
🇮🇳
Medanta-The Medicity, Gurgaon, Haryana, India

and more 7 locations